热门资讯> 正文

KalVista Pharmaceuticals GAAP每股收益为-3.69美元

2025-07-10 19:01

KalVista Pharmaceuticals press release (NASDAQ:KALV): FY GAAP EPS of -$3.69.
$220.6M in cash, providing runway into 2027

More on KalVista Pharmaceuticals

KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning
KalVista: Poised For Rare Disease Transformation
KalVista Pharmaceuticals rises after FDA nod for Ekterly
FDA's Makary sought to reject KalVista’s drug: report
Seeking Alpha’s Quant Rating on KalVista Pharmaceuticals

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。